Acronym |
Meaning |
ABG |
Arterial Blood Gas |
AIHA |
Autoimmune Hemolytic Anemia |
AE |
Adverse Event |
Alb |
Albumin |
ALC |
Absolute Lymphocyte Count |
ALL |
Acute Lymphoblastic Leukemia |
AML |
Acute Myeloid Leukemia |
ANC |
Absolute Neutrophil Count |
ASCO |
American Society of Clinical Oncology |
ASH |
American Society of Hematology |
B2M |
Beta2-Microglobulin |
BCL-2 |
B-cell lymphoma 2 |
BCR |
B-cell Receptor |
BM |
Bone Marrow |
BMBx |
Bone Marrow Biopsy |
BMT |
Bone Marrow Transplant |
BR |
Bendamustine and Rituximab |
BTK |
Bruton’s Tyrosine Kinase |
BUN |
Blood Urea Nitrogen |
Ca |
Calcium |
CAM |
Complementary and Alternative Medicine |
CAR-T |
Chimeric Antigen Receptor T-cell |
CBC |
Complete Blood Count |
CD |
Cluster of Differentiation |
CIT |
Chemo immuno Therapy |
CK |
Complex Karotype |
Cl |
Chlorine |
CLL |
Chronic Lymphocytic Leukemia |
CML |
Chronic Myeloid Leukemia |
CO2 |
Carbon Dioxide |
CP |
Convalescent Plasma |
Cr |
Creatinine |
CR |
Complete Response |
CRS |
Cytokine Release Syndrome |
Del (17p) |
17p Deletion |
DFS |
Disease Free Survival |
DLBCL |
Diffuse Large B-Cell Lymphoma |
DoR |
Duration of Response |
Dx |
Diagnosis |
Dz |
Disease |
EHA |
European Hematology Association |
EOT |
End of Treatment |
FCR |
Fludarabine, Cyclophosphamide, Rituximab |
FISH |
Fluorescence In Situ Hybridization |
GVHD |
Graft Versus Host Disease |
HCT |
Hematocrit |
HDMP |
High dose methyl-prednisolone |
HGB |
Hemoglobin level |
HLA |
Human Leukocyte Antigen |
HSCT |
Hematopoietic Stem Cell Transplant |
Hx |
History |
IAHA |
Idiopathic Autoimmune Hemolytic Anemia |
Ibr |
Ibrutinib |
IRC |
Independent Review Committee |
ITP |
Idiopathic (or Immune) Thrombocytopenic Purpura |
IwCLL |
International Workshop on CLL |
K |
Potassium |
LD |
Longest Diameter |
LDH |
Lactate Dehydrogenase |
LDT |
Lymphocyte Doubling Time |
LN |
Lymph Node |
MAB |
Monoclonal Antibodies |
MBL |
Monoclonal B-Cell Lymphocytosis |
MCH |
Mean Corpuscular Hemoglobin |
MCHC |
Mean Corpuscular Hemoglobin Concentration |
MCV |
Mean Corpuscular Volume |
MDS |
Myelodysplastic Syndromes |
MPV |
Mean Platelet Volume |
MRD |
Minimal or Measurable Residual Disease |
Na |
Sodium |
NGS |
Next Generation Sequencing |
O2 |
Oxygen |
ORR |
Overall Response Rate |
OS |
Overall Survival |
PB |
Peripheral Blood |
PCR |
Polymerase Chain Reaction |
PD |
Progressive Disease |
PFS |
Progression Free Survival |
PI3K |
Phosphoinositide 3-kinase |
PLT |
Platelets |
PR |
Partial Response/Partial Remission |
Pt |
Patient |
R |
Rituximab |
R/R |
Relapsed/Refractory |
RBC |
Red Blood Cell |
RCHOP |
Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone |
RDW |
Red cell Distribution Width |
RT |
Richter’s Transformation |
SCT |
Stem Cell Transplant |
SGPT |
Serum Glutamic Pyruvic Transaminase |
SL |
Synthetic Lethality |
SLL |
Small Lymphocytic Lymphoma |
TB4T |
Test Before Treat |
TBI |
Total Body Irradiation |
TKI |
Tyrosine Kinase Inhibitors |
TLS |
Tumor Lysis Syndrome |
TN |
Treatment Naive |
TTNT |
Time to Next Treatment |
TTP |
Time to Progression |
TTT |
Time to Treat |
Tx |
Treatment |
URI |
Upper Respiratory Infection |
VenR |
Venetoclax-Rituximab |
Vx |
Venetoclax |
W&W |
Watch and Wait |
WBC |
White Blood Cells |
WM |
Waldenstrom’s Macroglobulinemia |
Updated: February 4, 2021
-
Pingback: ESH 2014: Prof. Michael Hallek Discusses Clinical Trial Goals in CLL - CLL Society
-
Pingback: Clinical Trial Goals in CLL
-
Pingback: ASH 2014: Dr. Jan Burger on Ibrutinib Resistance in CLL (chronic lymphocytic leukemia): Next Steps: Transplants and Trials (Part 1) - CLL Society
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL
-
Pingback: New Targeted Therapies for Chronic Lymphocytic Leukemia
-
Pingback: Complex Karyotype in CLL Predicts Inferior Outcomes with Ibrutinib Therapy - CLL Society
-
Pingback: Symptoms of Chronic Lymphocytic Leukemia - CLL Society
-
Pingback: Diagnosis of Chronic Lymphocytic Leukemia - CLL Society
-
Pingback: ASH 2015: Dr. Stephan Stilgenbauer on Dramatic Responses to Venetoclax in relapsed/ refractory (R/R) 17p deleted CLL - CLL Society